Tags

Type your tag names separated by a space and hit enter

[Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline].
Presse Med 1986; 15(31):1559-61PM

Abstract

Ischemia and the metabolic disorder it entails would seem to be the pathogenic mechanism behind acute cochlear deafness, irrespective of the triggering process. The prognosis is entirely dependent on the rapid initiation of an effective treatment. At the end of a double-blind therapeutic trial comparing Ginkgo biloba extract and a standard alpha blocker (nicergoline), a significant recovery was observed in both therapeutic groups, but improvement was distinctly better in the Ginkgo biloba group.

Authors

No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

fre

PubMed ID

2947099

Citation

Dubreuil, C. "[Therapeutic Trial in Acute Cochlear Deafness. a Comparative Study of Ginkgo Biloba Extract and Nicergoline]." Presse Medicale (Paris, France : 1983), vol. 15, no. 31, 1986, pp. 1559-61.
Dubreuil C. [Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline]. Presse Med. 1986;15(31):1559-61.
Dubreuil, C. (1986). [Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline]. Presse Medicale (Paris, France : 1983), 15(31), pp. 1559-61.
Dubreuil C. [Therapeutic Trial in Acute Cochlear Deafness. a Comparative Study of Ginkgo Biloba Extract and Nicergoline]. Presse Med. 1986 Sep 25;15(31):1559-61. PubMed PMID: 2947099.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline]. A1 - Dubreuil,C, PY - 1986/9/25/pubmed PY - 1986/9/25/medline PY - 1986/9/25/entrez SP - 1559 EP - 61 JF - Presse medicale (Paris, France : 1983) JO - Presse Med VL - 15 IS - 31 N2 - Ischemia and the metabolic disorder it entails would seem to be the pathogenic mechanism behind acute cochlear deafness, irrespective of the triggering process. The prognosis is entirely dependent on the rapid initiation of an effective treatment. At the end of a double-blind therapeutic trial comparing Ginkgo biloba extract and a standard alpha blocker (nicergoline), a significant recovery was observed in both therapeutic groups, but improvement was distinctly better in the Ginkgo biloba group. SN - 0755-4982 UR - https://www.unboundmedicine.com/medline/citation/2947099/[Therapeutic_trial_in_acute_cochlear_deafness__A_comparative_study_of_Ginkgo_biloba_extract_and_nicergoline]_ L2 - http://www.diseaseinfosearch.org/result/2125 DB - PRIME DP - Unbound Medicine ER -